- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00468858
A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children
Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Caguas, Puerto Rico, 00725
- San Juan Batista Medical School
-
Carolina, Puerto Rico, 00983
- Private Practice
-
Ponce, Puerto Rico, 00733
- St Luke's Memorial Hospital
-
Rio Grande, Puerto Rico, 00745
- Caparra Internal Medicine Research Center
-
Rio Piedras, Puerto Rico, 00926
- Private Practice
-
Rio Piedras, Puerto Rico, 00935
- RCMI Clinical Research Center
-
San German, Puerto Rico, 00683
- Torre Medica San Vicente de Paul
-
San Juan, Puerto Rico, 00909-1711
- Clinical Research PR
-
San Juan, Puerto Rico, 00917
- Centro de Neumologia Pediatricia
-
San Juan, Puerto Rico, 00921
- Private Practice
-
San Juan, Puerto Rico, 00936-5067
- Dept Pediatria, Esc. De Medicina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:>
- Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.>
- A healthy male or non-pregnant female between 12 months (mths) and 50 years (yrs) of age at the time of the first vaccination;>
- Free of obvious health problems as established by medical history and physical examination before entering into the study;>
- For children: 23mths of age, full compliance with the United States Advisory Committee on Immunization Practices (U.S. ACIP) recommended childhood immunization schedule;>
- Written informed consent obtained from the subject or a parent/guardian and assent for subjects 7-20 yrs of age;>
- If the subject is female, she must be of non-childbearing potential, i.e. either pre-menarcheal, surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (i.e. intrauterine contraceptive device; condom and spermicide combination, oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days (dys) prior to vaccination, have a negative pregnancy test within 48 hrs prior to vaccination and must agree to continue such precautions for 60 dys after completion of the vaccination series. Any child who begins menarche during the study period must follow the same precautions listed above, from menarche until 60 dys after the second vaccine dose.>
Exclusion Criteria:>
- Pregnant or lactating female;>
- Female planning to become pregnant or planning to discontinue abstinence or contraceptive precautions;>
- History of any neurological or behavioral disorder or seizures, with the exception of a single febrile seizure in childhood; >
- History of allergic disease/reaction likely to be exacerbated by any component of the vaccine;>
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect, as determined by physical examination or laboratory tests;>
- Any confirmed or suspected immunosuppressive or immunodeficient condition;>
- Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever); note that vaccine can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., equivalent to an oral temperature <37.5°C/<99.5°F.>
- Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness;>
- Chronic splenomegaly, left upper quadrant abdominal pain or tenderness;>
- Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 dys preceding the first dose of study vaccine/placebo or planned use during the study period;>
- Planned administration of a vaccine not foreseen by the study protocol during the period starting from 30 dys before each dose of the study vaccine and ending 30 dys after; with the exception of standard infant and children "inactivated" vaccines or the inactivated influenza vaccine administered to adults or children; >
- A planned move to a location that will prohibit participating in the trial for the 12 mth duration;>
- Chronic administration (defined as more than 14 dys) of immunosuppressants or other immune-modifying drugs within 90 dys preceding the first dose or planned administration during the study period. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed;>
- Administration of immunoglobulins and/or blood products within 90 dys preceding the first dose or planned administration during the study period;>
- Hypertension;>
- Chest pain, palpitations, dizziness, shortness of breath unrelated to asthma, arrhythmias or friction rubs;>
- Any chronic systemic drug therapy to be continued during the study period (except for vitamin/mineral supplements, routine treatment for gastro-esophageal reflux);>
- Potential adult volunteers, or parents of potential child volunteers, who do not have easy access to a fixed or mobile telephone;>
- History of chronic alcohol consumption and/or drug abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Control
|
Lyophilized, single dose vials and sterile water for > injection; 0.5 mL dose; Vaccination schedule: 0, 6 months |
Experimental: T-DEN-Post-Transfection F17
Post-Transfection F17, full dose
|
Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
|
Experimental: T-DEN-Post-Transfection F19
Post-Transfection F19, full dose
|
Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Incidence of All and Grade 3 Solicited Local Symptoms
Time Frame: Within 21 days (days 0-20) f/up period after each vaccine dose
|
Incidence of all and grade 3 (prevents normal, everyday activities) solicited local and general symptoms within the 21-day follow-up period (Total vaccinated cohort)
|
Within 21 days (days 0-20) f/up period after each vaccine dose
|
Safety: Summary of Unsolicited Adverse Events Within the 31-day Post-vaccination Period
Time Frame: Within the 31-day (days 0-30) follow-up period after each vaccine dose
|
Summary of unsolicited Adverse Events within the 31-day post-vaccination period by age group (total vaccinated cohort)
|
Within the 31-day (days 0-30) follow-up period after each vaccine dose
|
Safety: Occurrence of Serious Adverse Events (SAEs)
Time Frame: 6 months + 30 day follow-up period after last vaccine dose
|
Summary of SAEs, 6 months + 30 day follow-up period after last vaccine dose
|
6 months + 30 day follow-up period after last vaccine dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Suspected and Laboratory Confirmed Dengue
Time Frame: 31-day (days 0-30) post-vaccination period and after 31-day period
|
Incidence of suspected and confirmed dengue reported during the 31-day (Days 0-30) post-vaccination period and after the 31-day period
|
31-day (days 0-30) post-vaccination period and after 31-day period
|
GMTs for Antibody Titer Above the Assay Cut Off to Each DEN Serotype for Unprimed and Primed Subjects
Time Frame: at month 7 (one month post dose 2)
|
Comparison of F17 and F19 formulations in terms of GMTs at month 7 (one month post dose 2) for each DEN type, -unprimed and primed subjects
|
at month 7 (one month post dose 2)
|
Percent of Subjects With Neut. Antibody Titer Above the Assay Cut-off to All Dengue Serotypes
Time Frame: Pre-vaccination, at post dose 1, months 3 and 6 and post dose 2, month 7
|
Monovalent, bivalent, trivalent and tetravalent response for DEN neut.
antibodies for unprimed and primed subjects
|
Pre-vaccination, at post dose 1, months 3 and 6 and post dose 2, month 7
|
Percent of Subjects With Neut. Sero-response to Each DEN Serotype
Time Frame: Pre-accination, at post dose 1, months 3 and 6 and post dose 2, month 7
|
Seropositivity rates for DEN neut.
antibodies for unprimed and primed subjects
|
Pre-accination, at post dose 1, months 3 and 6 and post dose 2, month 7
|
Vaccine Response to DEN Antibody at Post Dose 1, Month 3
Time Frame: at month 3, post dose 1
|
Vaccine response for DEN-1, DEN-2, DEN-3 and DEN-4 antibody S- = seronegative subjects (antibody titer <10 ED50 for DEN-1, 2, 3, and 4 prior to vaccination; S+ = Seropositive subjects (antibody titer >10 ED50 for DEN-1, 2, 3 and 4 prior to vaccination; Total = subjects either seropositive or seronegative at pre-vaccination Vaccine response defined as: For initially seronegative subjects, antibody titer >10 ED50 at PI(M3) and for initially seropositive subjects: antibody titer at PI(m3) >4 fold the pre-vaccination antibody titer |
at month 3, post dose 1
|
Vaccine Response to DEN Antibody at Post Dose 2, Month 7
Time Frame: at month 7, post dose 2
|
Vaccine response for DEN-1, DEN2, DEN-3, DEN-4 antibody at post dose 2, month 7
|
at month 7, post dose 2
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jorge Bertran-Pasarell, MD, Dept Medicina Interna Seccion Enfermedades Infecciosas
- Principal Investigator: Clemente Diaz-Perez, MD, University of PR
- Principal Investigator: Ines O. Esquilin-Rivera, MD, University of PR
- Principal Investigator: Evelyn Matta-Fontanet, MD, Caparra Internal Medicine Research Center
- Principal Investigator: Domingo Chardon-Feliciano, MD, Ponce School of Medicine
- Principal Investigator: Javier Morales-Ramirez, MD, Clinical Research PR
- Principal Investigator: Luis Rodriguez-Carrasquillo, MD, Private Practice, PR
- Principal Investigator: Jose Rodriguez-Santana, MD, Centro de Neumologia Pediatrica
- Principal Investigator: Miguel Sosa-Padilla, MD, Private Practice PR
- Principal Investigator: Jose Tavarez-Valle, MD, Private Practice, PR
- Principal Investigator: Alberto Santiago-Cornier, MD, Department of Molecular Medicine
- Principal Investigator: Anna Quintero, MD, San Juan Batista Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-14040
- WIRB number 20070071 (Other Identifier: Western Institutional Review Boards (WIRB))
- 106405 (Other Identifier: GSK)
- T-DEN-003 (Other Identifier: MRMC/WRAIR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue Fever
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusPuerto Rico, Colombia, Mexico, Honduras
Clinical Trials on T-DEN-Post-Transfection F17
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)Completed
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompleted
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompleted
-
Corporación de Rehabilitación Club de Leones Cruz...Colombian School of Engineering Julio GaravitoCompleted
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Ayman SaadCompletedHematologic Neoplasms | Graft-Versus-Host DiseaseUnited States
-
Seton Healthcare FamilyUniversity of TexasCompletedAsthmaUnited States
-
National Cancer Institute (NCI)CompletedMelanoma | Neoplasm MetastasisUnited States
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI)TerminatedPediatric Heart Transplantation | Pediatric Heart Transplant RecipientsUnited States, Canada
-
Center for International Blood and Marrow Transplant...National Marrow Donor ProgramCompletedChronic Lymphocytic Leukemia (CLL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chemotherapy-sensitive Lymphoma | Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma | Acute Biphenotypic Leukemia (ABL) | Acute Undifferentiated Leukemia (AUL)United States